Aytu BioPharma (AYTU) Competitors $2.36 +0.04 (+1.72%) As of 09:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. TCRX, EXOZ, CABA, JMAC, IGMS, PLRX, ZURA, EPIX, QNCX, and SRZNShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include TScan Therapeutics (TCRX), eXoZymes (EXOZ), Cabaletta Bio (CABA), Maxpro Capital Acquisition (JMAC), IGM Biosciences (IGMS), Pliant Therapeutics (PLRX), Zura Bio (ZURA), ESSA Pharma (EPIX), Quince Therapeutics (QNCX), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors TScan Therapeutics eXoZymes Cabaletta Bio Maxpro Capital Acquisition IGM Biosciences Pliant Therapeutics Zura Bio ESSA Pharma Quince Therapeutics Surrozen TScan Therapeutics (NASDAQ:TCRX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Does the media prefer TCRX or AYTU? In the previous week, TScan Therapeutics had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 1.87 beat TScan Therapeutics' score of 0.69 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Overall Sentiment TScan Therapeutics Positive Aytu BioPharma Very Positive Do analysts prefer TCRX or AYTU? TScan Therapeutics presently has a consensus target price of $7.80, indicating a potential upside of 319.35%. Aytu BioPharma has a consensus target price of $10.00, indicating a potential upside of 323.73%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than TScan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, TCRX or AYTU? Aytu BioPharma has higher revenue and earnings than TScan Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$4.42M23.81-$127.50M-$1.09-1.71Aytu BioPharma$81M0.26-$15.84M-$0.72-3.28 Do institutionals & insiders believe in TCRX or AYTU? 82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 4.4% of TScan Therapeutics shares are held by insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, TCRX or AYTU? TScan Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Is TCRX or AYTU more profitable? Aytu BioPharma has a net margin of 2.37% compared to TScan Therapeutics' net margin of -2,974.08%. Aytu BioPharma's return on equity of 3.51% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-2,974.08% -55.76% -36.56% Aytu BioPharma 2.37%3.51%0.91% SummaryAytu BioPharma beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.30M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-3.2920.3628.1819.72Price / Sales0.26290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book0.517.768.235.67Net Income-$15.84M-$55.11M$3.23B$257.51M7 Day Performance3.06%0.19%-0.61%-0.16%1 Month Performance19.80%10.80%6.63%9.89%1 Year Performance-16.31%-0.68%27.07%15.08% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma4.2891 of 5 stars$2.36+1.7%$10.00+323.7%-17.1%$21.30M$81M-3.29160TCRXTScan Therapeutics3.6843 of 5 stars$1.45-4.0%$7.80+437.9%-75.8%$85.45M$2.82M-1.33100EXOZeXoZymesN/A$10.18+2.7%N/AN/A$82.93M$70K0.0029Positive NewsGap DownCABACabaletta Bio2.9328 of 5 stars$1.49-8.6%$14.43+868.4%-78.5%$82.71MN/A-0.5950News CoverageJMACMaxpro Capital AcquisitionN/A$6.14-6.4%N/A+2,791.7%$82.45MN/A0.002,021IGMSIGM Biosciences4.6473 of 5 stars$1.35-0.7%$5.50+307.4%-89.1%$81.29M$2.68M-0.41190Positive NewsPLRXPliant Therapeutics4.4677 of 5 stars$1.18-6.3%$13.31+1,028.2%-90.1%$77.35M$1.58M-0.3390Positive NewsGap DownZURAZura Bio2.855 of 5 stars$1.10-2.7%$14.33+1,203.0%-66.1%$77.26MN/A-1.573EPIXESSA Pharma1.0082 of 5 stars$1.70-2.3%$2.00+17.6%-66.3%$77.24MN/A-2.7050QNCXQuince Therapeutics3.1243 of 5 stars$1.63+1.2%$8.00+390.8%+124.0%$73.21MN/A-1.1760News CoverageAnalyst ForecastSRZNSurrozen2.772 of 5 stars$8.35-0.1%$38.50+361.1%-11.6%$71.58M$10.65M-0.3380News CoveragePositive News Related Companies and Tools Related Companies TScan Therapeutics Alternatives eXoZymes Alternatives Cabaletta Bio Alternatives Maxpro Capital Acquisition Alternatives IGM Biosciences Alternatives Pliant Therapeutics Alternatives Zura Bio Alternatives ESSA Pharma Alternatives Quince Therapeutics Alternatives Surrozen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AYTU Stock Alerts